In the past week, ITCI stock has gone up by 15.12%, with a monthly gain of 18.88% and a quarterly surge of 9.32%. The volatility ratio for the week is 2.39%, and the volatility levels for the last 30 days are 2.40% for Intra-Cellular Therapies Inc. The simple moving average for the past 20 days is 14.13% for ITCI’s stock, with a 20.44% simple moving average for the past 200 days.
Is It Worth Investing in Intra-Cellular Therapies Inc (NASDAQ: ITCI) Right Now?
The 36-month beta value for ITCI is also noteworthy at 0.99. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ITCI is 98.77M, and at present, short sellers hold a 2.45% of that float. The average trading volume of ITCI on October 30, 2024 was 520.62K shares.
ITCI) stock’s latest price update
Intra-Cellular Therapies Inc (NASDAQ: ITCI)’s stock price has gone rise by 12.52 in comparison to its previous close of 76.75, however, the company has experienced a 15.12% increase in its stock price over the last five trading days. zacks.com reported 2024-10-30 that Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.25 per share a year ago.
Analysts’ Opinion of ITCI
Many brokerage firms have already submitted their reports for ITCI stocks, with Piper Sandler repeating the rating for ITCI by listing it as a “Overweight.” The predicted price for ITCI in the upcoming period, according to Piper Sandler is $92 based on the research report published on September 06, 2024 of the current year 2024.
Robert W. Baird, on the other hand, stated in their research note that they expect to see ITCI reach a price target of $83. The rating they have provided for ITCI stocks is “Outperform” according to the report published on January 03rd, 2024.
TD Cowen gave a rating of “Outperform” to ITCI, setting the target price at $75 in the report published on December 11th of the previous year.
ITCI Trading at 15.46% from the 50-Day Moving Average
After a stumble in the market that brought ITCI to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.74% of gains for the given period.
Volatility was left at 2.40%, however, over the last 30 days, the volatility rate increased by 2.39%, as shares surge +18.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.01% upper at present.
During the last 5 trading sessions, ITCI rose by +14.95%, which changed the moving average for the period of 200-days by +27.81% in comparison to the 20-day moving average, which settled at $75.66. In addition, Intra-Cellular Therapies Inc saw 20.58% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ITCI starting from ALEXANDRIA VENTURE INVESTMENTS, who proposed sale 25,000 shares at the price of $73.17 back on Sep 06 ’24. After this action, ALEXANDRIA VENTURE INVESTMENTS now owns shares of Intra-Cellular Therapies Inc, valued at $1,829,178 using the latest closing price.
Mates Sharon, the Chairman and CEO of Intra-Cellular Therapies Inc, sale 35,604 shares at $72.57 during a trade that took place back on Aug 29 ’24, which means that Mates Sharon is holding 1,070,329 shares at $2,583,884 based on the most recent closing price.
Stock Fundamentals for ITCI
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.93 for the gross margin
The net margin for Intra-Cellular Therapies Inc stands at -0.15. The total capital return value is set at -0.1. Equity return is now at value -9.63, with -8.29 for asset returns.
Based on Intra-Cellular Therapies Inc (ITCI), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -3.33. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -25.86.
Currently, EBITDA for the company is -158.85 million with net debt to EBITDA at 6.05. When we switch over and look at the enterprise to sales, we see a ratio of 14.9. The receivables turnover for the company is 3.87for trailing twelve months and the total asset turnover is 0.43. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.81.
Conclusion
In summary, Intra-Cellular Therapies Inc (ITCI) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
